We feel now is a pretty good time to analyse Numinus Wellness Inc.'s (TSE:NUMI) business as it appears the company may be on the cusp of a considerable accomplishment. Numinus Wellness Inc. provides solutions to develop and deliver psychedelic-assisted psychotherapy and transform the mental health. With the latest financial year loss of CA$45m and a trailing-twelve-month loss of CA$46m, the CA$51m market-cap company amplified its loss by moving further away from its breakeven target. Many investors are wondering about the rate at which Numinus Wellness will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company.
Check out our latest analysis for Numinus Wellness
According to some industry analysts covering Numinus Wellness, breakeven is near. They expect the company to post a final loss in 2025, before turning a profit of CA$8.8m in 2026. The company is therefore projected to breakeven around 3 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 63% year-on-year, on average, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.
Given this is a high-level overview, we won’t go into details of Numinus Wellness' upcoming projects, though, bear in mind that by and large a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
One thing we’d like to point out is that The company has managed its capital judiciously, with debt making up 1.1% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.
This article is not intended to be a comprehensive analysis on Numinus Wellness, so if you are interested in understanding the company at a deeper level, take a look at Numinus Wellness' company page on Simply Wall St. We've also put together a list of key aspects you should further examine:
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.